Plasma endocannabinoid alterations in individuals with substance use disorder are dependent on the "mirror effect" of schizophrenia

Frontiers in Psychiatry

Volumn 3, Issue SEP, 2012, Pages

  Desfossés, Joëlle ^a   Stip, Emmanuel ^b   Ait, Lahcen Bentaleb ^b   Lipp, Olivier ^a   Jean Pierre Chiasson, ^c   Furtos, Alexandra ^d   Venne, Karine ^d   Kouassi, Edouard ^a,e   Potvin, Stéphane ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Clinique du Nouveau Depart   (Canada)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Anandamide; Endocannabinoids; Oleoylethanolamide; Schizophrenia; Substance use disorder; Vulnerability marker

Indexed keywords

ANANDAMIDE; N OLEOYLETHANOLAMINE; QUETIAPINE;

ADULT; ARTICLE; BLOOD ANALYSIS; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE MARKER; DRUG EFFECT; ETHNICITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEGATIVE SYNDROME; POSITIVE SYNDROME; PRESCRIPTION; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT DURATION;

EID: 84867130956     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00085     Document Type: Article

References (48)

1. Adamczyk, P., McCreary, A. C., Przegalinski, E., Mierzejewski, P., Bienkowski, P., and Filip, M. (2009). The effects of fatty acid amide hydrolase inhibitors on maintenance of cocaine and food self-administration and on reinstatement of cocaine-seeking and food-taking behavior in rats. J. Physiol. Pharmacol. 60, 119-125.
2. Addington, D., Addington, J., and Maticka-Tyndale, E. (1993). Assessing depression in schizophrenia: the Calgary Depression Scale. Br. J. Psychiatry Suppl. 22, 39-44.
3. Ameri, A. (1999). The effects of cannabinoids on the brain. Prog. Neurobiol. 58, 315-348.
4. Arseneault, L., Cannon, M., Witton, J., and Murray, R. M. (2004). Causal association between cannabis and psychosis: examination of the evidence. Br. J. Psychiatry 184,110-117.
5. Cahill, K., and Ussher, M. H. (2011). Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst. Rev. 16, CD005353.
6. De Marchi, N., De Petrocellis, L., Orlando, P., Daniele, F., Fezza, F., and Di Marzo, V. (2003). Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 19, 2-5.
7. Dean, B., Sundram, S., Bradbury, R., Scarr, E., and Copolov, D. (2001). Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103, 9-15.
8. Desfossés,J.,Stip,E.,Bentaleb,L. A.,and Potvin,S. (2010). Endocannabinoids and schizophrenia. Pharmaceuticals 3, 3101-3126.
9. Drake, R. E., Osher, F. C., Noordsy, D. L., Hurlbut, S. C., Teague, G. B., and Beaudett, M. S. (1990). Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 16, 57-67.
10. D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y. T., Braley, G., Gueorguieva, R., and Krystal, J. H. (2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29, 1558-1572.
11. Economidou, D., Mattioli, L., Cifani, C., Perfumi, M., Massi, M., Cuomo, V., Trabace, L., and Ciccocioppo, R. (2006). Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (Berl.) 183, 394-403.
12. Femenia, T., Garcia-Gutierrez, M. S., and Manzanares, J. (2010). CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats. Alcohol. Clin. Exp. Res. 34, 131-141.
13. Fu, J., Gaetani, S., Oveisi, F., Lo Verme, J., Serrano, A., Rodriguez De Fonseca, F., Rosengarth, A., Luecke, H., Di Giacomo, B., Tarzia, G., and Piomelli, D. (2003). Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 425, 90-93.
14. Ginovart, N., Farde, L., Halldin, C., and Swahn,C. G. (1999). Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse 31, 154-162.
15. Giuffrida, A., Leweke, F. M., Gerth, C. W., Schreiber, D., Koethe, D., Faulhaber, J., Klosterkotter, J., and Piomelli, D. (2004). Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29, 2108-2114.
16. Giuffrida, A., Parsons, L. H., Kerr, T. M., Rodriguez de Fonseca, F., Navarro,M.,andPiomelli,D.(1999). Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2, 358-363.
17. Guillin, O., Abi-Dargham, A., and Laruelle, M. (2007). Neurobiology of dopamine in schizophrenia. Int. Rev. Neurobiol. 78, 1-39.
18. Hietala, J., Syvalahti, E., Vuorio, K., Nagren, K., Lehikoinen, P., Ruotsalainen, U., Rakkolainen, V., Lehtinen, V., and Wegelius, U. (1994). Striatal D2 dopamine receptor characteristics in neurolepticnaive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51, 116-123.
19. Hiley, C. R. (2009). Endocannabinoids and the heart. J. Cardiovasc. Pharmacol. 53, 267-276.
20. Hohmann, A. G., and Suplita, R. L. (2006). Endocannabinoid mechanisms of pain modulation. AAPS J. 8, 693-708.
21. Jablensky, A. (2000). Epidemiology of schizophrenia: the global burden of disease and disability. Eur. Arch. Psychiatry Clin. Neurosci. 250, 274-285.
22. Kampman, K. M., Pettinati, H. M., Lynch, K. G., Whittingham, T., Macfadden, W., Dackis, C., Tirado, C., Oslin, D. W., Sparkman, T., and O'Brien, C. P. (2007). A doubleblind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism. J. Clin. Psychopharmacol. 27, 344-351.
23. Kay, S. R., Fiszbein, A., and Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261-276.
24. Koethe, D., Giuffrida, A., Schreiber, D., Hellmich, M., Schultze-Lutter, F., Ruhrmann, S., Klosterkotter, J., Piomelli, D., and Leweke, F. M. (2009). Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br. J. Psychiatry 194, 371-372.
25. Laruelle, M. (1998). Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Q. J. Nucl. Med. 42, 211-221.
26. Lee, B., London, E. D., Poldrack, R. A., Farahi, J., Nacca, A., Monterosso, J. R., Mumford, J. A., Bokarius, A. V., Dahlbom, M., Mukherjee, J., Bilder, R. M., Brody, A. L., and Mandelkern, M. A. (2009). Striatal dopamine d2/d3 receptor availability is reduced in methamphetamine dependence and is linked to impulsivity. J. Neurosci. 29, 14734-14740.
27. Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., and Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10, 1665-1669.
28. Marczylo, T. H., Lam, P. M., Nallendran, V., Taylor, A. H., and Konje, J. C. (2009). A solid-phase method for the extraction and measurement of anandamide from multiple human biomatrices. Anal. Biochem. 384, 106-113.
29. Martinez,D.,Broft,A.,Foltin,R.W.,Slifstein, M., Hwang, D. R., Huang, Y., Perez, A., Frankle, W. G., Cooper, T., Kleber, H. D., Fischman, M. W., and Laruelle, M. (2004). Cocaine dependence and D2 receptor availability in the functional subdivisions of the striatum: relationship with cocaineseeking behavior. Neuropsychopharmacology 29, 1190-1202.
30. Martinotti, G., Andreoli, S., Di Nicola, M., Di Giannantonio, M., Sarchiapone, M., and Janiri, L. (2008). Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum. Psychopharmacol. 23, 417-424.
31. Matias, I., and Di Marzo, V. (2007). Endocannabinoids and the control of energy balance.Trends Endocrinol. Metab. 18, 27-37.
32. Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yasar, S., Goldberg, S. R., and Pistis, M. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. J. Neurosci. 28, 13985-13994.
33. Nunez, L. A., and Gurpegui, M. (2002). Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia. Acta Psychiatr. Scand. 105, 173-178.
34. Pacher, P., Batkai, S., and Kunos, G. (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. 58, 389-462.
35. Perala,J.,Suvisaari,J.,Saarni,S.I.,Kuoppasalmi, K., Isometsa, E., Pirkola, S., Partonen, T., Tuulio-Henriksson, A., Hintikka, J., Kieseppa, T., Harkanen, T., Koskinen, S., and Lonnqvist, J. (2007). Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch. Gen. Psychiatry 64, 19-28.
36. Pertwee, R. G. (2005). Pharmacological actions of cannabinoids. Handb. Exp. Pharmacol. 168, 1-51.
37. Potvin, S., Kouassi, E., Lipp, O., Bouchard, R. H., Roy, M. A., Demers, M. F., Gendron,A.,Astarita, G., Piomelli, D., and Stip, E. (2008). Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy. J. Psychopharmacol. (Oxford) 22, 262-269.
38. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., and Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264, 2511-2518.
39. Rizkallah, E., Stip, E., Zhornitsky, S., Pampoulova, T., Gendron, A., Rompre, P. P., Chiasson, J. P., and Potvin, S. (2010). Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial. Expert Opin. Pharmacother. 11, 2947-2951.
40. Sobell, L. C., Toneatto, T., Sobell, M. B., Leo, G. I., and Johnson, L. (1992). Alcohol abusers' perceptions of the accuracy of their selfreports of drinking: implications for treatment. Addict. Behav. 17, 507-511.
41. Stopponi, S., Somaini, L., Cippitelli, A., Cannella, N., Braconi, S., Kallupi, M., Ruggeri, B., Heilig, M., Demopulos, G., Gaitanaris, G., Massi, M., and Ciccocioppo, R. (2011). Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol. Psychiatry 69, 642-649.
42. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Ding, Y. S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., Gifford, A., Wong, C., and Pappas, N. (2001). Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158, 2015-2021.
43. Volkow, N. D., Fowler, J. S., Wang, G. J., Hitzemann, R., Logan, J., Schlyer, D. J., Dewey, S. L., and Wolf, A. P. (1993). Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse 14, 169-177.
44. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Hitzemann, R., Ding, Y. S., Pappas, N., Shea, C., and Piscani, K. (1996). Decreases in dopamine receptors but not in dopamine transporters in alcoholics. Alcohol. Clin. Exp. Res. 20, 1594-1598.
45. Wang, G. J., Volkow, N. D., Fowler, J. S., Logan, J., Abumrad, N. N., Hitzemann, R. J., Pappas, N. S., and Pascani,K. (1997). Dopamine D2 receptor availability in opiate-dependent subjects before and after naloxoneprecipitated withdrawal. Neuropsychopharmacology 16, 174-182.
46. Wong, D. F., Kuwabara, H., Horti, A. G., Raymont, V., Brasic, J., Guevara, M., Ye, W., Dannals, R. F., Ravert, H. T., Nandi, A., Rahmim, A., Ming, J. E., Grachev, I., Roy, C., and Cascella, N. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52, 1505-1513.
47. Yu, L. L., Zhou, S. J., Wang, X. Y., Liu, J. F., Xue, Y. X., Jiang, W., and Lu, L. (2011). Effects of cannabinoid CB receptor antagonist rimonabant on acquisition and reinstatement of psychostimulant reward memory in mice. Behav. Brain Res. 217, 111-116.
48. Zhornitsky, S., Stip, E., Desfosses, J., Pampoulova, T., Rizkallah, E., Rompre, P. P., Bentaleb, L. A., Lipp, O., Chiasson, J. P., Gendron, A., and Potvin, S. (2011). Evolution of substance use, neurological and psychiatric symptoms in schizophrenia and substance use disorder patients: a 12-week, pilot, case-control trial with quetiapine. Front. Psychiatry 2:22. doi:10.3389/fpsyt.2011.00022